drugset / Trial / NCT00433953

Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

NCT00433953

Phase 1 Terminated 44 enrolled Children's Hospital Medical Center, Cincinnati
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how genes influence the response to mycophenolate mofetil (CellCept) in children who have had a kidney transplant. The study will look at how differences in some genes effect blood levels of mycophenolate mofetil over time in children, how often side effects occur and the way that children respond to mycophenolate mofetil. The results may lead to better dosing based on individual needs.

Timeline

Start
2007-02
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule

Indications

No indication recorded.